WO1998008524A1 - Multimineral products useful in achieving autonomic balance - Google Patents
Multimineral products useful in achieving autonomic balance Download PDFInfo
- Publication number
- WO1998008524A1 WO1998008524A1 PCT/US1997/014967 US9714967W WO9808524A1 WO 1998008524 A1 WO1998008524 A1 WO 1998008524A1 US 9714967 W US9714967 W US 9714967W WO 9808524 A1 WO9808524 A1 WO 9808524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meg
- composition according
- minerals
- vary
- levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Abstract
Multimineral products targeted to specific groups.
Description
MULTIMINERAL PRODUCTS USEFUL IN ACHIEVING AUTONOMIC BALANCE
Cross Reference to Related Application
This application is a continuation-in-part of Application Serial No. 08/744,549, filed November 6, 1996, which is a continuation-in-part of Application Serial No. 08/703,308, filed August 26, 1996.
Technical Field The present invention relates generally to multimineral products.
It is becoming more and more accepted that the autonomic nervous system is very important in the health of individuals. Individuals are members of one of three groups - sympathetic, parasympathetic or balanced. Members of each group react differently to certain foods and agents than do members of the other groups. This is an important factor to be considered when prescribing minerals to be taken by an individual.
People also fall into three other categories depending on the type of diet under which they best survive. These categories are moderate vegetarian, balanced and moderate carnivore.
Because of lack of the proper diet, exercise and exogenous factors, people do not maintain autonomic balance. The sympathetic and parasympathetic autonomic nervous system types fall into these three diet types with the sympathetic type being more vegetarian and the parasympathetic more carnivore.
The present inventors have found that by using certain minerals at certain levels in a unit dose provides for enhanced performance. This is different from the prior art since balancing the autonomic nervous system is targeted for the first time. That a purpose of the present invention is to provide unit doses of minerals.
That a further purpose is to provide unit doses of minerals containing levels of minerals which vary depending on the individual characteristics as discussed above.
That a further objective of the present invention is to provide methods of combating diseases by using such unit doses. These and other objectives will become evident from the detailed description given below.
All percentages and ratios used herein are by weight unless otherwise specified. Also all measurements referred to herein are made at 25°C.
Summary Of The Invention The present invention relates to multimineral compositions in unit dose form. Detailed Description Of The Invention
The unit dose compositions comprise a multiple of minerals. The history of minerals and their properties are given in greater detail below:
Minerals
The minerals used in the present compositions include the following: Boron Between 1939 and 1947, several attempts to induce a boron deficiency in rats were unsuccessful. As a result, boron was generally accepted as essential for plants (suggested in 1910, confirmed in 1923), but not for animals. Since 1982, however, evidence has accumulated that indicates boron is an essential nutrient for animals and humans.
The target level of Boron used in the compositions of the present invention is about 150 meg in the products for balanced vegetarian and about 160 meg in the products for balanced carnivore. Calcium The role of calcium as a structural material in bones and teeth has been known for centuries. Prehistoric man suffered from osteoporosis, and although great progress has been made in the last few decades toward quantifying and understanding this disease, much remains to be understood about the importance of dietary calcium intake as a causative, preventative, or therapeutic factor. In addition to calcium's structural role in bone and teeth, it is now recognized that all living cells require calcium to conduct their specialized functions. Intracellular calcium acts as a second messenger and enables cells to respond to stimuli such as hormones or neurotransmitters. Movement of calcium from intracellular compartments to the cytosol initiates events such as cell division, secretion, a . nd movement.
The target level of Calcium used in the compositions of the present invention is about 90 mg in the products for balanced vegetarian and about 275 mg in the products for balanced carnivore.
Chromium By 1948, chromium was recognized as a consistent component of plant and animal tissue. The first suggestion that chromium might have biologic activity appeared in 1954, when it was found that chromium enhanced the synthesis of cholesterol and fatty acids from acetate by rat liver. In 1959, trivalent chromium was identified as the active component of the "glucose tolerance factor," which alleviated the impaired glucose tolerance in rats fed certain diets apparently inadequate in chromium. Between 1964 and 1968, the first reports appeared that indicated chromium could affect glucose tolerance in humans. In these studies, mildly diabetic patients, or subjects with impaired glucose tolerance, received supplements of 2.72 to 3.62 μmol (150 to 200 μg) Cr per day as chromium chloride; the supplementation improved the impaired glucose tolerance of 40 to 50% of these individuals. Subsequently, it was found that the chromium supplementation also decreased serum cholesterol concentrations and normalized the exaggerated insulin responses to glucose loads. Despite these suggestive findings, chromium was not generally accepted as essential for humans until 1977, when chromium deficiency signs in the patient receiving total parenteral nutrition (TPN) were described. Shortly thereafter, other patients receiving TPN were found to exhibit abnormalities of glucose metabolism that were responsive to chromium supplementation.
The target level of Chromium used in the compositions of the present invention is about 85 meg in the products for balanced vegetarian and about 80 meg in the products for balanced carnivore.
Copper Copper hias been used therapeutically smce at least 400 B.C., when Hippocrates prescribed copper compounds for pulmonary and other diseases. The use of copper compounds in the treatment of diseases reached its peak in the nineteenth century and subsequently declined when the treatments were not successful.
Copper was identified as a normal constituent of blood and its toxicity was described in the late nineteenth century. By 1900, an anemia that could not be prevented by iron supplements has been observed in animals kept on a whole-milk diet. In 1928, Hart reported that this anemia in rats was responsive to iron only when copper supplements were also given. Experiments in several animals species produced similar results and suggested that copper deficiency anemia occurs in all species. Detailed reviews of the early history of copper have been published.
Human disease was first linked to copper metabolism shortly after Wilson's disease was described in 1912, and long before the condition was recognized as an inborn error of metabolism in 1953. As early as 1930, a relationship between anemia in humans and copper deficiency was suspected, but copper supplements only improved hemoglobin synthesis in some instances, so the hypothesis was not well accepted. Conclusive evidence of copper deficiency in humans was not reported until 1964. Menkes' disease, another genetic disorder, was described in 1962 and recognized as a disorder of copper absorption in 1972. Since about 1950, an mcreasuig number of diseases that are not specifically disorders of copper metabolism have been associated with altered, usually increased, levels of copper in blood or other tissues.
An official dietary copper recommendation, an Estimated Safe and Adequate Daily Dietary Intake of 31 to 47 μmoi (2 to 3 mg), was first introduced in 1979. The lower end of this range was reduced to 24 μmol (1.5 mg) in 1989.
The target level of Copper used in the compositions of the present invention is about 0.50 mg in the products for balanced vegetarian and about 0.30 mg in the products for balanced carnivore.
Germanium Grayish-white solid, a p-type semiconductor, conductivity depends largely on added impurities, d 5.323, p 937.4C, bp 2830C, oxidizes readily at 600-700C, does not volatilize approximately 1350C, hardness 6 on Mohs scale. Attached by nitric acid and aqua regia, stable to water, acids and alkalies in absence of dissolved oxygen.
The target level of Germanium used in the compositions of the present invention is about 9.0 mg in the products for balanced vegetarian and about 8.0 mg in the products for balanced carnivore. Magnesium Magnesium plays an essential role in a wide range of fundamental cellular reactions. Hence, it is not surprising that deficiency in the organism may lead to serious biochemical and symptomatic changes. McCollum and associates made the first systematic observations of
magnesium deficiency in rats and dogs in the early 1930s. The first description of clinical depletion in man was published in 1934 in a small number of patients with various underlying diseases. Flink and associates in the early 1950s initiated their long-term studies documenting depletion of this ion in alcoholics and in patients on magnesium-free intravenous solutions. Although the diets consumed by healthy Americans do not appear to lead to clinically significant hypomagnesemia, an increasing number of clinical disorders have been found to be associated with magnesium depletion. Experimental and clinical observations have revealed important interrelations of this essential ion with other electrolytes, second messengers, hormones and growth factors, their membrane receptors, signal pathways, ion channels, parathyroid hormone secretion and action, vitamin D metabolism, and bone functions.
The target level of Magnesium used in the compositions of the present invention is about 90 mg in the products for balanced vegetarian and about 30 mg in the products for balanced carnivore.
Manganese Although manganese was known to be a constituent of animal tissues as early as 1913, it was not until 1931 that manganese deficiency was shown to induce poor growth in mice and abnormal reproduction in rats. Manganese deficiency has since been induced in numerous species of animals, but not in humans, although several well-designed attempts have been made.
The target level of Manganese used in the compositions of the present invention is about 9.0 mg in the products for balanced vegetarian and about 10 mg in the products for balanced carnivore.
Molybdenum Evidence for the essentially of molybdenum first appeared in 1953, when xanthine oxidase was identified as a molybdenum metalloenzyme. Subsequently, attempts to produce molybdenum deficiency signs in rats and chickens were successful only when the diet contained massive amounts of tungsten, an antagonist of molybdenum metabolism. These studies showed that the dietary requirement to maintain normal growth of animals was less than 10.4 nmol
( 1 μg) molybdeπum/g diet, an amount substantially lower than requirements for other trace elements recognized as essential at the time. Thus, molybdenum was not considered of much practical importance in animal and human nutrition. Consequently, over the past 35 years, relatively little effort has been devoted to studying the metabolic and pathologic consequences of molybdenum deficiency in monogastric animals or humans.
The target level of Molybdenum used in the compositions of the present invention is about 34 meg in the products for balanced vegetarian and about 34 meg in the products for balanced carnivore.
Potassium Potassium is the most abundant intracellular cation, with an average concentration of about 150 mEq L; the extracellular concentration ranges from 3.5 to 5 mEq/L. The average total exchangeable potassium for hospitalized adult males is 42.7 mEq kg body weight, whereas the future for women is about 10% less. The normal value of total exchangeable potassium is 8 to 15% less than that of total body potassium.
The two most important physiologic functions of its role as the major determinant of intracellular ionic strength The transmembrane electrical potential of most cells is determined by the ratio of intracellular to extracellular potassium concentration; in muscle the transmembrane electrical potential is about 90mv with the inside of the cell negative to the outside The membrane potential (Em) is calculated from the Nernst equation
Em = -60 Ku^ Kex' where Km and K ex are intracellular and extracellular potassium concentrations, respectively When the ratio is about 30 to I, the E-→→. is normal at -90 mv Because the extracellular potassium concentration is altered more readily in most clinical situations, transmembrane electrical potential is influenced more by the K→-.κ than by the Kjj,
Potassium, being the major intracellular ion, is the mam determinant of intracellular ionic strength Cellular ionic strength greatly influences cellular metabolism as evidenced by the marked clinical abnormalities attributable to cell overhydration or dehydration In addition, potassium has specific roles in various enzymatic reactions of the cell, such as in protein and glycogen synthesis. The target level of Potassium used in the compositions of the present invention is about 35 mg in the products for balanced vegetarian and about 15 mg in the products for balanced carnivore
Selenium Selenium first attracted practical biological interest in the 1930s when it was found to cause alkali disease, a chronic poisonmg of livestock lesulting from the consumption of plants that grow on high-selenium soils. Then, n 1957, Schwarz discovered that trances of selenium prevented liver necrosis in vitamm E-deficient rats Soon thereafter deficiencies of selenium and vitamin E were shown to be involved in several economically important nutritional diseases m cattle, sheep, swine, and poultry The first demonstration of a biochemical function for selenium in mammals came in 1973 when it was shown to be a constituent of the enzyme glutathione peroxidase Reports documenting the importance of selenium in human nutrition appeared in 1979 Information about the role of selenium in human nutntion increased rapidly in the 1980s, and a Recommended Dietary Allowance for selenium was established in 1989
The target level of Selenium used in the compositions of the present invention is about 35 meg in the products for balanced vegetarian and about 40 meg in the products for balanced carnivore. Silica Colorless crystals or white powder, odorless and tasteless, d 2 2-2 6, insoluble in water and acids except hydrogen fluoride, soluble in molten aikai when finely divided and .amorphous Combines chemically with most metallic oxides; melts to a glass with lowest known coefficient of expansion (fused silica); thermal conductivity about half that of glass, mp 171 OC, bp 2230C, high dielectric constant, high heat and shock resistance Noncombustible The target level of Silica used in the compositions of the present invention is about 5 0 mg in the products for balanced vegetarian and about 2 0 mg in the products for balanced carnivore
Vanadium In 1876, Priestly reported on the toxicity of sodium vanadate. It was not until 1912, however, that the first paper on pharmacologic and toxicologic actions of vanadium appeared. At this time, high vanadium concentrations were discovered in the blood of ascidian worms. The hypothesis that vanadium may play a physiologic role in higher animals has had a long and inconclusive history. In 1950, it was stated that, "we are completely ignorant of the physiological role of vanadium in animals, where its presence is constant." In 1963, after a review of the early studies on vanadium essentiality, Schroeder et al. concluded that, although vanadium behaves like an essential trace metal, final proof of essentiality for mammals was still lacking. Between 1971 and 1974, a number of findings reported by four different research groups led many people to conclude that vanadium is an essential nutrient. Many of these findings, however, may have been the consequence of high vanadium supplements (10 to 100 times the amount normally found in the diet) that induced pharmacologic changes in suboptimaily performing animals fed unbalanced diets. The most substantive evidence for vanadium essentiality has appeared only since 1987.
The target level of Vanadium used in the compositions of the present invention is about 18 meg in the products for balanced vegetarian and about 22 meg in the products for balanced carnivore.
Zinc Zinc (Zn) was recognized as a distinct element in 1509. Evidence of its essentiality was demonstrated in plants in 1869 and in animals in 1934. Because of its wide prevalence in foodstuffs, naturally occurring Zn deficiency was considered unlikely until 1955, when swine parakeratosis was shown to be a Zn-deficiency disease. That humans could suffer from Zn deficiency was suggested by observations that malnourished Chinese patients during World War II had low concentrations of plasma Zn. In 1956, a conditioned Zn-deficiency syndrome in humans was demonstrated. Since 1961, when the endemic hypogonadism and dwarfism of rural Iran was suggested to be derived from Zn deficiency, there has been an increasing appreciation of the magnitude of both the clinical .and the public health significance of Zn-deficiency states.
The target level of Zinc used in the compositions of the present invention is about 12.0 mg in the products for balanced vegetarian and about 12.0 mg in the products for balanced carnivore.
The levels given above can be varied by ± 20% of the level stated, preferably ± 10% of the level given. Other Components
In addition to the minerals, other components may be added to the unit dose mixture, but care needs to be taken to ensure that the components do not interfere with the ability of the minerals to perform their functions. Suitable additional components include such materials as carboxymethyl cellulose. Methods of Manufacture
The minerals can simply be mixed together in a dry state and put into a suitable unit dose delivery device such as a capsule, sachet or other unit dose which does not involve significant
compression. The unit doses can also be mixed with an appropriate solvent such as water to form a solution or suspension before use and can be used by patients who prefer liquids or are unable to take materials by mouth through use of intravenous or peroneal infusion.
Composition Use The unit dose compositions of the present invention are ingested in the same manner as other unit doses are. Oftentimes, the unit dose is ingested with the aid of water or other liquid.
The following examples further describe and demonstrate preferred compositions of the present invention. The examples are given solely for illustration and are not to be considered as limitations of this invention as many variations thereof are possible without departing from the spirit and scope of the invention.
Example 1 Balanced Carnivore Multimineral Specifications
Form Amt in Multimineral
Boron citrate 160 meg
Calcium carbonate 275 mg
Chromium picolinate 80 meg
Copper gluconate 0.3 mg
Germanium 132 8 mg
Magnesium carbonate 30 mg
Manganese glycerophosphate 10 mg
Molybdenum Na moiybdenate 34 meg
Potassium PABA 15 mg
Selenium selenomethionine 40 meg
Silica horsetail 2 mg
Vanadium penoxide 22 meg
Zinc sulfate 12 mg
Example 2 Balanced Vegetarian Multimineral Specifications Form Amt in Multimineral
Boron citrate 50 meg
Calcium phosphate 90 mg
Chromium picolinate 85 meg
Copper gluconate 0.5 mg
Germanium 132 9 mg
Magnesium carbonate 90 mg
Manganese glycerophosphate 9 mg
Molybdenum Na moiybdenate 34 meg
Potassium citrate 35 mg
Selenium selenomethionine 35 meg
Silica horsetail 5 mg
Vanadium penoxide 18 meg
Zinc sulfate 12 mg
Example 3
New Moderate Carnivore Multimineral Specifications
Form Amt in Multimineral
Boron aminoate 150 meg
Calcium carbonate 90 mg
Chromium niacinate 80 meg
Copper gluconate 0.33 mg
Germanium 132 5 mg
Manganese glycerophosphate 5 mg
Molybdenum Na moiybdenate 35 meg
Selenium Na selenite 25 meg
Silica horsetail 3 mg
Vanadium pentoxide 16 meg
Zinc sulfate 12 mg
Example 4
New Moderate Vegetarian Multimineral Specifications
Form Amt in Multimineral
Boron aminoate 40 meg
Calcium phosphate 3 mg
Chromium picolinate 165 meg
Copper sulfate 1 mg
Germanium 132 10 mg
Magnesium oxide 70 mg
Manganese citrate 7 mg
Molybdenum yeast 35 meg
Potassium citrate 18 mg
Selenium selenomethionine 25 meg
Silica horsetail 0.5 mg
Vanadium yeast 4 meg
Zinc sulfate 9 mg
It is to be appreciated, of course, that the composition described in the Examples can be dosed in one single dose or in multiple doses, such as two or three or more, so long as the total dosage amount is met.
Claims
WHAT IS CLAIMED IS
1 A multimineral unit dose composition comprising
Component Form Amount
Boron citrate 160 meg
Calcium carbonate 275 mg
Chromium picolinate 80 meg
Copper gluconate 0 3 mg
Germanium 132 8 mg
Magnesium carbonate 30 mg
Manganese glycerophosphate 10 g
Molybdenum Na moiybdenate 34 meg
Potassium PABA 15 mg
Selenium selenomethionine 40 meg
Silica horsetail 2 mg
Vanadium penoxide 22 meg
Zinc sulfate 12 mg
A composition according to Claim 1 wherein the levels stated may vary by ± 20%
A composition according to Claim 1 wherein the levels may vary by ± 10%
A multimineral unit dose composition comprising
Component Form Amount
Boron citrate 150 meg
Calcium phosphate 90 mg
Chromium picolinate 85 meg
Copper gluconate 0 5 mg
Germanium 132 9 mg
Magnesium carbonate 90 mg
Manganese glycerophosphate 9 mg
Molybdenum Na moiybdenate 34 meg
Potassium citrate 35 mg
Selenium selenomethionine 35 meg
Silica horsetail 5 mg
Vanadium penoxide 18 meg
Zinc sulfate 12 mg
A composition according to Claim 4 wherein the levels stated may vary by ± 20%.
A composition according to Claim 4 wherein the levels may vary by ± 10%.
A multimineral unit dose composition comprising:
Component Form Amount
Boron aminoate 150 meg
Calcium carbonate 90 mg
Chromium niacinate 80 meg
Copper gluconate 0.33 I mg
Germanium 132 5 mg
Manganese glycerophosphate 5 mg
Molybdenum Na moiybdenate 35 meg
Selenium Na selenite 25 meg
Silica horsetail 3 mg
Vanadium pentoxide 16 meg
Zinc sulfate 12 mg
8. A composition according to Claim 7 wherein the levels stated may vary by ± 20%.
9. A composition according to Claim 7 wherein the levels may vary by ± 10%.
10. A multimineral unit dose composition comprising:
Component Form Amount
Boron aminoate 40 meg
Calcium phosphate 3 mg
Chromium picolinate 165 meg
Copper sulfate 1 mg
Germanium 132 10 mg
Magnesium oxide 70 mg
Manganese citrate 7 mg
Molybdenum yeast 35 meg
Potassium citrate 18 mg
Selenium selenomethionine 25 meg
Silica horsetail 0.5 mg
Vanadium yeast 4 meg
Zinc sulfate 9 mg
11 A composition according to Claim 10 wherein the levels stated may vary by ± 20%.
12. A composition according to Claim 10 wherein the levels may vary by ± 10%.
13 A composition according to Claim 1 wherein said composition is dissolved/suspended for use through the mouth of the individual or by IV or peroneal infusion.
14 A method of providing minerals to a person in need of such minerals by dosing them with a composition according to Claim 1
15 A method according to Claim 14 wherein the dosage is provided by a multiple of small dosages
16 A method of providing minerals to a person in need of such minerals by dosing them with a compositions according to Claim 4
17 A method according to Claim 4 wherein the dosage is provided by a multiple of smaller dosages
18 A method of providing minerals to a person in need of such minerals by dosing them with a composition according to Claim 7
19. A method according to Claim 7 wherein the dosage is provided by a multiple of small dosages.
20. A method of providing minerals to a person in need of such minerals by dosing them with a composition according to Claim 10
21 A method according to Claim 10 wherein the dosage is provided by a multiple of small dosage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU41621/97A AU4162197A (en) | 1996-08-26 | 1997-08-26 | Multimineral products useful in achieving autonomic balance |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70330896A | 1996-08-26 | 1996-08-26 | |
| US08/703,308 | 1996-08-26 | ||
| US74454996A | 1996-11-06 | 1996-11-06 | |
| US08/744,549 | 1996-11-06 | ||
| US83310997A | 1997-04-04 | 1997-04-04 | |
| US08/833,109 | 1997-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998008524A1 true WO1998008524A1 (en) | 1998-03-05 |
Family
ID=27418757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/014967 WO1998008524A1 (en) | 1996-08-26 | 1997-08-26 | Multimineral products useful in achieving autonomic balance |
Country Status (6)
| Country | Link |
|---|---|
| AU (1) | AU4162197A (en) |
| CO (1) | CO4900076A1 (en) |
| ID (1) | ID19681A (en) |
| MA (1) | MA24992A1 (en) |
| PE (1) | PE24899A1 (en) |
| WO (1) | WO1998008524A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0916270A2 (en) * | 1997-11-18 | 1999-05-19 | EnergyBalance AG | Mineral-mixture with improved taste |
| EP1124438A1 (en) * | 1998-11-06 | 2001-08-22 | Nucycle Therapy Inc. | Nutritional supplements |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002867A1 (en) * | 1985-11-14 | 1987-05-21 | Vita Tech International, Inc. | Hydrolyzed protein chelates |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
| US5597550A (en) * | 1994-12-09 | 1997-01-28 | Buxing Mo | Apparatus and method for administering minerals |
-
1997
- 1997-08-25 CO CO97048863A patent/CO4900076A1/en unknown
- 1997-08-26 WO PCT/US1997/014967 patent/WO1998008524A1/en active Application Filing
- 1997-08-26 AU AU41621/97A patent/AU4162197A/en not_active Abandoned
- 1997-08-26 MA MA24776A patent/MA24992A1/en unknown
- 1997-08-26 PE PE1997000758A patent/PE24899A1/en not_active Application Discontinuation
- 1997-08-26 ID IDP972977A patent/ID19681A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002867A1 (en) * | 1985-11-14 | 1987-05-21 | Vita Tech International, Inc. | Hydrolyzed protein chelates |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
| US5597550A (en) * | 1994-12-09 | 1997-01-28 | Buxing Mo | Apparatus and method for administering minerals |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0916270A2 (en) * | 1997-11-18 | 1999-05-19 | EnergyBalance AG | Mineral-mixture with improved taste |
| EP0916270A3 (en) * | 1997-11-18 | 1999-12-08 | EnergyBalance AG | Mineral-mixture with improved taste |
| EP1124438A1 (en) * | 1998-11-06 | 2001-08-22 | Nucycle Therapy Inc. | Nutritional supplements |
| EP1124438A4 (en) * | 1998-11-06 | 2005-02-02 | Nucycle Therapy Inc | Nutritional supplements |
Also Published As
| Publication number | Publication date |
|---|---|
| ID19681A (en) | 1998-07-30 |
| PE24899A1 (en) | 1999-03-17 |
| CO4900076A1 (en) | 2000-03-27 |
| AU4162197A (en) | 1998-03-19 |
| MA24992A1 (en) | 2000-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510922A (en) | Formulation containing calcium, magnesium, zinc and vitamin D3 for prevention and recovery of osteoporosis | |
| Nordstrom | Trace mineral nutrition in the elderly | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| Shils | Minerals in total parenteral nutrition | |
| EP1003370B1 (en) | Method of enhancing magnesium absorption and prevention of atherosclerosis | |
| CN101642468A (en) | Pharmaceutical composition for lowering blood glucose and blood lipids | |
| KR20100103520A (en) | Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly | |
| WO1998008524A1 (en) | Multimineral products useful in achieving autonomic balance | |
| KR20080008155A (en) | Nutritional composition comprising vitamins, minerals, or fermented natural substances especially necessary for koreans | |
| US20070042020A1 (en) | Composition for the treatment of dysfunctional energy metabolism syndrome | |
| CN112544847A (en) | Sports solid beverage for enhancing endurance and preparation method thereof | |
| Linder | Other trace elements and the liver | |
| US4591506A (en) | Oral ingestion of indium | |
| EP2606900A1 (en) | Enhancement of magnesium uptake in mammals | |
| CN101601681A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| JPS62171654A (en) | Composition for enhancing cell metabolism | |
| EP1675598B1 (en) | Nutrition trace element composition | |
| Solomons | Trace elements in nutrition of the elderly: 1. Established RDAs for iron, zinc, and iodine | |
| Anderson et al. | EDTA chelation therapy does not selectively increase chromium losses | |
| Belavady | Amino acid imbalance and pellagra | |
| CN101584736A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN108514122A (en) | The preparation method of minerals supplementing preparation | |
| Watson | Trace Element Requirements of the Elderly | |
| Kassam et al. | A new form of speudohypoparathyroidism type II with abnormal response to TRH: 37 | |
| CN101601726A (en) | The pharmaceutical composition that is used for blood sugar lowering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998511814 Format of ref document f/p: F |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |